| abstract |
Referring to a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein: R1 is hydrogen or C1-C6-alkyl; R2, R3 and R4 are hydrogen, C1-C6-alkyl, C1-C6-alkoxy, halo-C1-C6-alkyl, among others; X is CH or N; m and n are both 1; or m and n are both 0; A is selected from C6-C14-aryl and 5- to 14-membered heteroaryl; RL is selected from hydrogen and C1-C6-alkyl. Preferred compounds are: rac-cis-6-(4-(5-chloro-1-methyl-1H-indol-3-yl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4 ]oxazin-3(4H)-one; rac-cis-6-(4-(9H-fluoren-9-yl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3- b][1,4]oxazin-3(4H)-one; among others. It is also referred to a pharmaceutical composition. Said compounds are inhibitors of monoacylglycerol lipase (MAGL) and are useful in the treatment or prophylaxis of neuroinflammation, neurodegenerative diseases, pain, cancer, mental disorders, multiple sclerosis, Alzheimer's disease, Parkinson's disease, among others. |